Internal Server Error

About Erganeo

Erganeo is a venture capital firm founded in 2012. It is primarily based out of Paris, France. As of Dec 2021, Erganeo has invested in 27 companies. It primarily invests in Seed round in France based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and High Tech. Most recently it participated in the $***** Seed round of Orixha Overall, Erganeo portfolio has seen 2 acquisitions, namely Open Agora. A lot of funds co-invest with Erganeo, with names like INFIPLAST sharing a substantial percentage of its portfolio. Erganeo has team of 7 people including 1 partners.
Key Metrics
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Seed & Series A
Portfolio Acquisitions

Erganeo's List of Top Investments

Erganeo has a portfolio of 27 companies. Their most notable investments are in Orixha and Ermium Therapeutics.Their portfolio spans across and France. They have invested in Life Sciences, HealthTech, High Tech and 13 other sectors, across stages such as Seed, Series A stages. Here is the list of top investments by Erganeo:
EVerZom develops a technology platform for the production of extracellular vesicles. The extracellular vesicles are generated by Mesenchymal stem cells having regenerative properties. This method can be used to apply turbulence stimulation to cells.

Key facts about EVerZom

  • Founded Year: 2018
  • Location: Paris (France)
  • Stage: Seed
  • Total Funding till date: $1.32M
  • Employee Count: 26 as on Oct 31, 2026
  • Investors: EIC Fund, Bpifrance and 3 Others
  • Latest Funding Round: Grant (prize money), Jun 17, 2025, $*****
  • Highlight: Editors' Pick
Developer of liquid ventilation technology for critical care patient treatment. The system enables controlled hypothermia for patients experiencing post cardiac arrest syndrome. This technology focuses on the rapid cooling of biological systems to improve clinical outcomes. The approach utilizes breathable liquid to stabilize body temperatures during critical care interventions.

Key facts about Orixha

  • Founded Year: 2017
  • Location: Maisons Alfort (France)
  • Stage: Seed
  • Total Funding till date: $2.25M
  • Employee Count: 15 as on Oct 31, 2026
  • Investors: EIC Fund, EIT Health and 3 Others
  • Latest Funding Round: Grant (prize money), Jun 2022, $*****
Ermium Therapeutic is developing therapies for auto-immune inflammatory diseases. The leading candidate of the company is CXCR4 which has antagonists action and can regulate the inflammation. The candidate helps in the production of type 1 interferons by plasmacytoid dendritic cells (pDC)for treating inflammatory diseases. The diseases targeted by the candidate are multiple sclerosis, rheumatoid arthritis, inflammatory bowel diseases, and others.

Key facts about Ermium Therapeutics

Developer of exosome-based therapeutic solutions for gastrointestinal diseases. The company is engaged in the development of cell-free regenerative medicine EVOGEX that helps in treating gastrointestinal fistula that is an abnormal opening in the stomach or intestines that allows the contents to leak & other GI-related indications.

Key facts about Evora Biosciences

MilliDrop develops benchtop automated instruments that allow handling and analysis of up to 10,000 reactions in parallel. Its first cell culture Machin; MilliDrop Analyzer based on milli fluidics technology for bacteriological research and diagnosis purposes. Its technology has already been validated in microbiology for the screening of algae, fungi, bacteria, and yeasts as well as for antimicrobial susceptibility testings.

Key facts about Millidrop

Erganeo's Investments by Stage

Erganeo has made 1 investment in Seed stage with an average round size of $2.25M and 1 investment in Series A stage with an average round size of $6.96M.

Erganeo's Investments by Sector

Erganeo has a portfolio focused on Life Sciences. Notably, it has invested in 17 Tech companies, 15 Enterprise (B2B) companies, 6 Software companies and at least 3 companies focusing on Tech hardware.

Erganeo's Investments by Geography

Erganeo has made most investments in France (2).

Erganeo's recent investments

Erganeo has not made any investment in 2026 so far.
Here are the most recent investments by Erganeo:
Date
Company
Location
Round Details
Round Amount
Co-Investors
Dec 10, 2021
France
Seed
2481
Sep 11, 2019
France
Series A
3746

Acquired companies in Erganeo's Portfolio

2 companies from Erganeo's portfolio have been acquired. The most recent acquisition was Open Agora in Sep 2020 by Jamespot for $*****.
Here are Erganeo's portfolio companies that got acquired most recently:
Company
Acquisition Date
First Invested on
First Round of Investment
Round Size
Sep 22, 2020
-
-
1642
Apr 22, 2020
-
-
5700

Team profile of Erganeo

Erganeo has a team of 7 members including 1 Partner and 1 Principal located in France. Erganeo's team does not sit on the board of any company as of now.

Co-investors of Erganeo

Over the past 7 years, 8 investors have co-invested in Erganeo's portfolio companies. This includes only funds.

  • Invested before Erganeo: EIT Health has invested before Erganeo.
  • Top Co-investors of Erganeo: 5 investors entered a company along with Erganeo. These include investors like INFIPLAST (1 company).
  • Invested after Erganeo: EIC Fund (1 company) and Fountain Healthcare Partners (1 company) are the investors which have invested in Erganeo's portfolio after their investments.

Recent News related to Erganeo

View all news related to Erganeo

FAQs about Erganeo

Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford